IL312485A - T-cell modulatory multimeric polypeptides and methods of use thereof - Google Patents
T-cell modulatory multimeric polypeptides and methods of use thereofInfo
- Publication number
- IL312485A IL312485A IL312485A IL31248524A IL312485A IL 312485 A IL312485 A IL 312485A IL 312485 A IL312485 A IL 312485A IL 31248524 A IL31248524 A IL 31248524A IL 312485 A IL312485 A IL 312485A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- methods
- multimeric polypeptides
- polypeptides modulate
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283028P | 2021-11-24 | 2021-11-24 | |
| US202263309288P | 2022-02-11 | 2022-02-11 | |
| US202263338131P | 2022-05-04 | 2022-05-04 | |
| PCT/US2022/080263 WO2023097188A1 (en) | 2021-11-24 | 2022-11-21 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312485A true IL312485A (en) | 2024-07-01 |
Family
ID=86540434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312485A IL312485A (en) | 2021-11-24 | 2022-11-21 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240317815A1 (https=) |
| EP (1) | EP4436600A4 (https=) |
| JP (1) | JP2024541334A (https=) |
| KR (1) | KR20240114745A (https=) |
| AU (1) | AU2022398342A1 (https=) |
| CA (1) | CA3236566A1 (https=) |
| IL (1) | IL312485A (https=) |
| WO (1) | WO2023097188A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2025207816A1 (en) * | 2024-03-27 | 2025-10-02 | Cue Biopharma, Inc. | Treatment of b-cell mediated immune disorders by t-cell mediated depletion of b cells, plasmablasts and plasma cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103649125A (zh) * | 2011-06-22 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞 |
| WO2019051126A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2020181273A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| WO2020181272A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| KR20220015382A (ko) * | 2019-05-29 | 2022-02-08 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| WO2021195108A1 (en) * | 2020-03-24 | 2021-09-30 | Cue Biopharma, Inc. | T cell modulatory polypeptides and methods of use thereof |
-
2022
- 2022-11-21 WO PCT/US2022/080263 patent/WO2023097188A1/en not_active Ceased
- 2022-11-21 IL IL312485A patent/IL312485A/en unknown
- 2022-11-21 KR KR1020247019611A patent/KR20240114745A/ko active Pending
- 2022-11-21 AU AU2022398342A patent/AU2022398342A1/en active Pending
- 2022-11-21 CA CA3236566A patent/CA3236566A1/en active Pending
- 2022-11-21 EP EP22899490.1A patent/EP4436600A4/en active Pending
- 2022-11-21 JP JP2024527498A patent/JP2024541334A/ja active Pending
-
2024
- 2024-06-06 US US18/736,261 patent/US20240317815A1/en not_active Abandoned
-
2025
- 2025-05-14 US US19/208,098 patent/US20250376491A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236566A1 (en) | 2023-06-01 |
| EP4436600A4 (en) | 2025-10-01 |
| US20240317815A1 (en) | 2024-09-26 |
| WO2023097188A1 (en) | 2023-06-01 |
| AU2022398342A1 (en) | 2024-05-16 |
| JP2024541334A (ja) | 2024-11-08 |
| EP4436600A1 (en) | 2024-10-02 |
| KR20240114745A (ko) | 2024-07-24 |
| US20250376491A1 (en) | 2025-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL297617B1 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| IL312485A (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| IL281505A (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| DK3910714T3 (da) | Elektrolyt og elektrokemisk indretning | |
| EP3749338A4 (en) | HUMANIZED BCMA ANTIBODY AND BCMA CAR T CELLS | |
| EP3897690A4 (en) | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF | |
| DK3830120T3 (da) | Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1 | |
| EP3971200C0 (en) | CELL CULTURE SCAFFOLDING MATERIAL AND CELL CULTURE CONTAINER | |
| IL286695A (en) | Modulators of cell surface protein interactions and methods and compositions related to same | |
| EP3950720A4 (en) | Fusion protein and use thereof | |
| EP4103586A4 (en) | POLYPEPTIDES AND THEIR USES | |
| EP3712268A4 (en) | TRANSFORMED HUMAN CELL AND ITS USE | |
| EP4428232A4 (en) | Isolated Cas13 protein and its use | |
| IL290910A (en) | Modified tff2 polypeptides containing compositions and methods of use thereof | |
| EP3604546A4 (en) | SYSTEM OF PROTEIN EXPRESSION IN A PLANT CELL AND ASSOCIATED USE | |
| IL269433A (en) | Chimeric polypeptides and methods of altering their localization in the cell membrane | |
| EP3725875A4 (en) | RECOMBINANT ADENOVIRUS AND STEM CELLS WITH IT | |
| EP3808835A4 (en) | CELL CULTURE SYSTEM AND CELL CULTURE PROCESS | |
| EP3808833A4 (en) | CELL CULTURE SYSTEM AND CELL CULTURE PROCESS | |
| EP4444324A4 (en) | MODIFIED T CELL RECEPTORS AND THEIR USES | |
| EP3585809A4 (en) | THIOLISOMERASE INHIBITORS AND USES THEREOF | |
| IL286116A (en) | Expression of nitrogenase polypeptides in plant cells | |
| IL286477A (en) | T cell expressing an fc gamma receptor and methods of use thereof | |
| DK3697804T3 (da) | REKOMBINANT EKSPRESSION AF PCV2b-ORF2-PROTEIN I INSEKTCELLER | |
| EP3842518A4 (en) | CELL CULTURE METHOD AND CELL CULTURE DEVICE |